Antisense modulation of integrin beta 5 expression
AssigneeIsis Pharmaceuticals, Inc.
InventorsScott Cooper, Kenneth W. Dobie
Life of this patent
Estimating the term…
Abstract
Antisense compounds, compositions and methods are provided for modulating the expression of integrin beta 5. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding integrin beta 5. Methods of using these compounds for modulation of integrin beta 5 expression and for treatment of diseases associated with expression of integrin beta 5 are provided.
Claims20
A compound 8 to 80 nucleobases in length targeted to a nucleic acid molecule encoding integrin beta 5, wherein said compound specifically hybridizes with said nucleic acid molecule encoding integrin beta 5 and inhibits the expression of integrin beta 5.
A compound 8 to 80 nucleobases in length which specifically hybridizes with at least an 8-nucleobase portion of a preferred target region on a nucleic acid molecule encoding integrin beta 5.
A method of screening for an antisense compound, the method comprising the steps of:
- a. contacting a preferred target region of a nucleic acid molecule encoding integrin beta 5 with one or more candidate antisense compounds, said candidate antisense compounds comprising at least an 8-nucleobase portion which is complementary to said preferred target region, and
- b. selecting for one or more candidate antisense compounds which inhibit the expression of a nucleic acid molecule encoding integrin beta 5.
Dependencies are inferred from the claim text.